[
    [
        {
            "time": "2018-07-31",
            "original_text": "Assessing Eli Lilly’s Human Pharmaceutical Segment in Q2 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Human Pharmaceutical Segment",
                    "Q2 2018",
                    "earnings",
                    "revenue growth"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Assessing Eli Lilly’s Human Pharmaceutical Segment in Q2 2018",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        }
    ]
]